RxDoctor Payments Data

Jake Trinidad, MD

Ophthalmology · San Antonio, TXNPI 1861787418

Payments from drug & device makers

$3,384in general payments, 2019–2025

Across 111 payments — averaging $30.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$655
  • Alcon$618
  • Rxsight Inc$354
  • Ocular Therapeutix, Inc.$339
  • Sun Pharmaceutical Industries Inc.$317
  • AbbVie$297
  • plus $803 from 14 others

What the payments were for

  • Speaking & faculty fees$752%
  • Food & beverage$3,02589%
  • Gifts$50%
  • Other$2808%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,384 in reported general payments places this provider in the 60th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$89,700
Medicare patients
188
Services billed
669

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast26$18,888
TyrvayaVarenicline Tartrate16$15,263
Cyclosporine12$8,486
RestasisCyclosporine11$8,014
Prednisolone Acetate142$5,242
LumiganBimatoprost14$5,054
RocklatanNetarsudil Mesylat/Latanoprost12$4,175
Loteprednol Etabonate26$3,462
Brimonidine Tartrate14$3,454
MoxifloxacinMoxifloxacin Hcl112$2,518
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol21$2,126
Ketorolac Tromethamine129$1,904
Difluprednate11$818
Latanoprost64$655
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha33$314

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra$54$18,88826 claims
Oyster Point Pharma, Inc.Tyrvaya$245$15,26316 claims
AbbVieRestasis, Lumigan$297$13,06825 claims
Aerie Pharmaceuticals, Inc.Rocklatan$54$4,17512 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$16$3,46226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →